Evidence map›Paper›PMID 30209775›Full record

ArticleDocumenta ophthalmologica. Advances in ophthalmology2018

Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation.

Katharina Messias, Rafael de Montier Barroso, Rodrigo Jorge, Andre Messias

Abstract read
PubMed Publisher
In one paragraph

Article in Documenta ophthalmologica. Advances in ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Katharina MessiasDepartment of Ophthalmology, Otolaryngology and Head and Neck Surgery, Ribeirão Preto School of Medicine, Av. Bandeirantes 3900, Ribeirão Prêto, SP, 14049-900, Brazil.
Rafael de Montier BarrosoDepartment of Ophthalmology, Otolaryngology and Head and Neck Surgery, Ribeirão Preto School of Medicine, Av. Bandeirantes 3900, Ribeirão Prêto, SP, 14049-900, Brazil.
Rodrigo JorgeDepartment of Ophthalmology, Otolaryngology and Head and Neck Surgery, Ribeirão Preto School of Medicine, Av. Bandeirantes 3900, Ribeirão Prêto, SP, 14049-900, Brazil.
Andre MessiasDepartment of Ophthalmology, Otolaryngology and Head and Neck Surgery, Ribeirão Preto School of Medicine, Av. Bandeirantes 3900, Ribeirão Prêto, SP, 14049-900, Brazil. amessias@usp.br.ORCID 0000-0002-5328-9608
Clinics Hospital of Ribeirão Preto · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare retinal function changes in eyes with proliferative diabetic retinopathy (PDR) after intravitreal ranibizumab (IVR), combined or not with conventional (ETDRS) or multispot laser panretinal (PASCAL) photocoagulation (PRP).

methodsThis study included laser-naive PDR patients that required PRP. Eyes were randomly and prospectively assigned to receive IVR or IVR combined with PASCAL or EDTRS. PRP was performed at baseline in 1 (PASCAL) or 2 (ETDRS) sessions. In eyes with macular edema, macular short pulse grid laser was associated with IVR at baseline and IVR was repeated monthly or quarterly if neovascularization was detected on angiography. Comprehensive ophthalmological evaluations, including SD-OCT, were performed at baseline and every 4 weeks after treatment. Full-field electroretinography (ERG: extended ISCEV standard) was performed at baseline and at 12, 24 and 48 weeks.

resultsIVR = 13, PASCAL = 15 and ETDRS = 15 eyes finished 48-week follow-up. There was a statistically significant BCVA improvement of 0.1-0.3 logMAR in all groups, and fluorescein angiography leakage area (FLA) reduced in 56%, 73%, and 73% from baseline for ETDRS, IVR and PASCAL, respectively, up to 48 weeks without significant differences between groups (p > 0.05). A significant a- and b-wave amplitudes reduction was observed for dark- and light-adapted ERG for ETDRS and PASCAL, but only minor dark-adapted b-wave reduction was found for IVR, up to 48 weeks. As an example, at week 48, combined response b-wave amplitude reduced in 181.5 ± 31.4 µV, 128.0 ± 27.9 µV and 82.4 ± 15.2 µV for ETDRS, PASCAL and IVR (p < 0.05 each group), respectively. No significant difference was observed between ETDRS and PASCAL for any ERG parameter.

conclusionsIVR combined with single or multiple spot PRP causes similar retinal function impairment during 48 weeks of observation, while IVR alone seems to be similarly effective controlling FLA without changing retinal function.

Indexed as

Laser CoagulationAngiogenesis InhibitorsCombined Modality TherapyDiabetic RetinopathyElectroretinographyFemaleFluorescein AngiographyHumansIntravitreal InjectionsMaleMiddle AgedRanibizumabRetinaRetinal NeovascularizationTomography, Optical CoherenceVascular Endothelial Growth Factor AAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor AVEGFA protein, humanAnti-VEGFDiabetic retinopathyElectroretinographyRetinal photocoagulation

Identifiers

PMID30209775
OpenAlexW2890034246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.